Navigation Links
Reverse engineering epilepsy's 'miracle' diet
Date:5/25/2012

For decades, neurologists have known that a diet high in fat and extremely low in carbohydrates can reduce epileptic seizures that resist drug therapy. But how the diet worked, and why, was a mysteryso much so that in 2010, The New York Times Magazine called it "Epilepsy's Big, Fat Miracle."

Now, researchers at Dana-Farber Cancer Institute and Harvard Medical School have proposed an answer, linking resistance to seizures to a protein that modifies cellular metabolism in the brain. The research, to be published in the May 24th issue of the journal Neuron, may lead to the development of new treatments for epilepsy.

The research was led jointly by Nika Danial, HMS assistant professor of cell biology at Dana-Farber Cancer Institute, and Gary Yellen, professor of neurobiology at Harvard Medical School. The first author was Alfredo Gimnez-Cassina, a research fellow in Danial's lab.

Epilepsy is a neurological disorder characterized by repeated seizures, an electrical storm in the brain that can manifest as convulsions, loss of motor control, or loss of consciousness. Some cases of epilepsy can be improved by a diet that drastically reduces sugar intake, triggering neurons to switch from their customary fuel of glucose to fat byproducts called ketone bodies. The so-called ketogenic diet, which mimics effects of starvation, was described more than 80 years ago and received renewed interest in the 1990s. Recent studies corroborate that it works, but shed little light on how.

"The connection between metabolism and epilepsy has been such a puzzle," said Yellen, who was introduced to the ketogenic diet through his wife, Elizabeth Thiele, HMS professor of neurology, who directs the Pediatric Epilepsy Program at MassGeneral Hospital for Children, but was not directly involved in the study. "I've met a lot of kids whose lives are completely changed by this diet," Yellen said. "It's amazingly effective, and it works for many kids for whom drugs don't work."

"We knew we needed to come at this link between metabolism and epilepsy from a new angle," said Danial, who had previously discovered a surprising double duty for a protein known for its role in apoptosis: The protein, BCL-2-associated Agonist of Cell Death, or BAD, also regulated glucose metabolism.

Gimnez-Cassina further discovered that certain modifications in BAD switched metabolism in brain cells from glucose to ketone bodies. "It was then that we realized we had come upon a metabolic switch to do what the ketogenic diet does to the brain without any actual dietary therapy," said Gimenez-Cassina, who went on to show that these same BAD modifications protect against seizures in experimental models of epilepsy. Still, it wasn't clear exactly how.

Yellen suspected the solution involved potassium ion channels. While sodium and calcium ion channels tend to excite cells, including neurons, potassium channels tend to suppress cell electrical activity. His lab had previously linked ketone bodies to the activation of ATP-sensitive potassium (KATP) channels in neurons. Yellen had hypothesized that the ketogenic diet worked because ketone bodies provide neurons enough fuel for normal function, but when the electrical and energy storm of an epileptic seizure threatens, the activated KATP channels can shut the storm down. But the effects of diets are broad and complex, so it was impossible to say for sure.

The effects that Danial's lab had discoveredBAD's ability to alter metabolism and seizuresoffered a new avenue for studying the therapeutic effects of altered metabolism. Together, the researchers decided to investigate whether Danial's switch governed Yellen's pathway, and whether they could reverse engineer the seizure protection of a ketogenic diet.

They could. Working in genetically altered mice, the researchers modified the BAD protein to reduce glucose metabolism and increase ketone body metabolism in the brain. Seizures decreased, but the benefit was erased when they knocked out the KATP channelstrong evidence that a BAD-KATP pathway conferred resistance to epileptic seizures. Further experiments suggested that it was indeed BAD's role in metabolism, not cell death that mattered. The findings make the BAD protein a promising target for new epilepsy drugs.

"Diet sounds like this wholesome way to treat seizures, but it's very hard. I mean, diets in general are hard, and this diet is really hard," said Yellen, whose wife's Center for Dietary Therapy in Epilepsy hosts a candy-free Halloween party for its many patients on the ketogenic diet. "So finding a pharmacological substitute for this would make lots of people really happy."


'/>"/>

Contact: David Cameron
david_cameron@hms.harvard.edu
617-432-0441
Harvard Medical School
Source:Eurekalert

Related biology technology :

1. Groundbreaking National Program to Reverse Obesity Expands to 50 Locations
2. Soligenix Announces 1 for 20 Reverse-Split of its Common Stock
3. Stem cell therapy reverses diabetes
4. Rosetta Genomics Announces One-For-Four Reverse Stock Split
5. Reverse NanoJapan: Rice to host 25-30 Japanese students
6. Cord Blood America Announces Reverse Stock Split Takes Effect Monday, May 9, 2011
7. Spherix Announces Reverse Stock Split Effective May 6, 2011
8. Cord Blood America: Shareholders Approve Common Stock Reverse Split
9. Spherix to Effect Reverse Stock Split
10. GenVec, Inc. Announces Effectiveness of Reverse Stock Split
11. Advanced Life Sciences Announces 2010 Fourth Quarter and Full Year Financial Results and Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... ... device-to-computer interconnect using USB or PCI Express, announced the ZEM5310 USB 3.0 FPGA ... FPGA into a compact business-card sized form factor suitable for prototyping, testing, and ...
(Date:1/18/2017)... ... 2017 , ... Executive search firm Slone Partners proudly supports ... the advancement of the clinical trials segment. Hosted in Miami, this conference brings ... and management. , As executive talent specialists in the industries central to ...
(Date:1/18/2017)... ... January 18, 2017 , ... Researchers from a new study are stating that if ... after prostate cancer treatment, this indicates there is still remaining prostate cancer cells that are ... The PSA test has always been an indicator of whether a man’s prostate cancer ...
(Date:1/18/2017)... 2017 Shareholder rights law firm Johnson & ... board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: ... the proposed sale of the Company to Eli Lilly ... small molecules for the acute treatment of migraines. ... signed a definitive merger agreement with Eli Lilly. Under ...
Breaking Biology Technology:
(Date:1/12/2017)... , Jan. 12, 2017  Trovagene, Inc. (NASDAQ: ... (ctDNA) technologies, today announced that it has signed agreements ... and the Middle East ... milestone marks the first wave of international distribution agreements ... and blood samples. The initial partners will ...
(Date:1/12/2017)... , January 12, 2017 A new report by Allied Market ... the global biometric technology market is expected to generate revenue of $10.72 billion by ... Continue Reading ... Allied Market Research Logo ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
(Date:1/11/2017)... 2017  Michael Johnson, co-founder of Visikol Inc. a company originally ... been named to the elite "Forbes 30 Under 30" list in ... people in 20 fields nationwide to be recognized as a leader ... were selected. ... is currently a PhD candidate at Rutgers University. ...
Breaking Biology News(10 mins):